BTG Enters IVC Market With $150M Novate Bolt-On

The diversified UK firm is betting $20m upfront and up to $150m total on a novel inferior vena cava filter technology.

BTG PLC has added Irish inferior vena cava filter firm Novate Medical Ltd. to complement its vascular device portfolio. The acquisition, announced Sept. 7, will cost $20m upfront, plus up to $130m in milestone payments.

Novate's Sentry device was 510(k)-cleared in 2017 and is the first bioconvertible IVC filter, meaning it integrates into the vessel...

More from Deals

More from Business